ArticleBMC clinical pathology2012
Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors.
Article in BMC clinical pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- Revisiting the Tenascins: Exploitable as Cancer Targets?Frontiers in oncology · 2022Review
- Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression.International journal of molecular sciences · 2021Review
- Latent TGF-β Activation Is a Hallmark of the Tenascin Family.Frontiers in immunology · 2021Article
- Hold on or Cut? Integrin- and MMP-Mediated Cell-Matrix Interactions in the Tumor Microenvironment.International journal of molecular sciences · 2020Review
- Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects.Current cancer drug targets · 2020Review
- Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.Frontiers in immunology · 2020Article
- Tenascin-W: Discovery, Evolution, and Future Prospects.Frontiers in immunology · 2020Article
- The extracellular matrix in tumor progression and metastasis.Clinical & experimental metastasis · 2019Review
- The Expression and Possible Functions of Tenascin-W During Development and Disease.Frontiers in cell and developmental biology · 2019Review
- Synthetic scaffolds for musculoskeletal tissue engineering: cellular responses to fiber parameters.NPJ Regenerative medicine · 2019Review
- Sarcolab pilot study into skeletal muscle's adaptation to long-term spaceflight.NPJ microgravity · 2018Article
- Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers.Nature communications · 2017Article
- Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.Advanced drug delivery reviews · 2016Review
- Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells.International journal of cancer · 2015Article
- Mechanism of irradiation-induced mammary cancer metastasis: A role for SAP-dependent Mkl1 signaling.Molecular oncology · 2015Article
- Tenascin-C Signaling in melanoma.Cell adhesion & migration · 2015Review
- Transcriptional regulation of tenascin genes.Cell adhesion & migration · 2015Review
- Tenascin-C: Form versus function.Cell adhesion & migration · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTenascins are large glycoproteins found in the extracellular matrix of many embryonic and adult tissues. Tenascin-C is a well-studied biomarker known for its high overexpression in the stroma of most solid cancers. Tenascin-W, the least studied member of the family, is highly expressed in the stroma of colon and breast tumors and in gliomas, but not in the corresponding normal tissues. Other solid tumors have not been analyzed. The present study was undertaken to determine whether tenascin-W could serve as a cancer-specific extracellular matrix protein in a broad range of solid tumors.
methodsWe analyzed the expression of tenascin-W and tenascin-C by immunoblotting and by immunohistochemistry on multiple frozen tissue microarrays of carcinomas of the pancreas, kidney and lung as well as melanomas and compared them to healthy tissues.
resultsFrom all healthy adult organs tested, only liver and spleen showed detectable levels of tenascin-W, suggesting that tenascin-W is absent from most human adult organs under normal, non-pathological conditions. In contrast, tenascin-W was detectable in the majority of melanomas and their metastases, as well as in pancreas, kidney, and lung carcinomas. Comparing lung tumor samples and matching control tissues for each patient revealed a clear overexpression of tenascin-W in tumor tissues. Although the number of samples examined is too small to draw statistically significant conclusions, there seems to be a tendency for increased tenascin-W expression in higher grade tumors. Interestingly, in most tumor types, tenascin-W is also expressed in close proximity to blood vessels, as shown by CD31 co-staining of the samples.
conclusionsThe present study extends the tumor biomarker potential of tenascin-W to a broad range of solid tumors and shows its accessibility from the blood stream for potential therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.